Golden State Equity Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Golden State Equity Partners’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,380	Closed	-$1.79M	–	1177
2026 Q1	$1.79M	Hold	19,380	–	–	0.14%	179
2025 Q4	$1.53M	Hold	19,380	–	–	0.25%	83
2025 Q3	$1.42M	Hold	19,380	–	–	0.24%	99
2025 Q2	$986K	Hold	19,380	–	–	0.18%	138
2025 Q1	$873K	Hold	19,380	–	–	0.17%	153
2024 Q4	$801K	Sell	19,380 -1,300	-6%	-$54.2K	0.15%	160
2024 Q3	$807K	Buy	20,680 +750	+4%	+$29.9K	0.13%	181
2024 Q2	$681K	Buy	+19,930	New	+$523K	0.14%	163
2023 Q4	$559K	Buy	18,930 +950	+5%	+$28.8K	0.14%	172
2023 Q3	$568K	Hold	17,980	–	–	0.16%	152
2023 Q2	$465K	Hold	17,980	–	–	0.13%	192
2023 Q1	$432K	Buy	+17,980	New	+$410K	0.23%	106
2022 Q1	$412K	Hold	18,730	–	–	0.21%	121
2021 Q4	$299K	Buy	+18,730	New	+$291K	0.15%	128

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's MIRM Position: Q2 2026 in Review

Golden State Equity Partners sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 19,380 shares — an estimated $1.79M sold.

Golden State Equity Partners first reported a position in MIRM in Q4 2021 and held it in 14 quarters. The position peaked at $1.79M in Q1 2026. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Golden State Equity Partners reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 19,380 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.79M.
Golden State Equity Partners first reported a position in Mirum Pharmaceuticals in Q4 2021 and held it in 14 quarters.
Golden State Equity Partners's Mirum Pharmaceuticals position peaked at $1.79M in Q1 2026.
328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.